Form 4: IRADIMED CEO Sells 5,000 Shares Under 10b5-1 Plan

IRADIMED CEO Roger E. Susi sold 5,000 shares of common stock on October 27, 2025, through a pre-arranged 10b5-1 trading plan.

Summary

• Roger E. Susi, the CEO, President, and Chairman of IRADIMED CORP (IRMD), reported the sale of 5,000 shares of the company's common stock.
• The transactions took place on October 27, 2025.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Susi on June 16, 2025.
• The shares were sold from the Phillip Susi 2008 Dynasty Trust, an entity through which Mr. Susi has indirect beneficial ownership.
• The weighted average sale prices for the transactions were $77.56, $78.33, and $79.12 per share.
• Following these reported transactions, the Phillip Susi 2008 Dynasty Trust indirectly holds 2,327,500 shares.
• Mr. Susi also indirectly beneficially owns 162,950 shares through the Roger E. Susi Revocable Trust and 2,062,500 shares through the Matthew Susi 2008 Dynasty Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, these sales were executed under a pre-arranged Rule 10b5-1 trading plan, which indicates a scheduled transaction rather than a reaction to new, adverse information. This typically reduces the perceived negative signal.

Negatives

• The sale of 5,000 shares by a key executive, even if pre-planned, could be perceived by some investors as a reduction in insider conviction, although the 10b5-1 plan mitigates this interpretation.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide information directly related to broader industry trends or competitive landscape for IRADIMED CORP.

Related Party Transactions

• The reported sales were made by the Phillip Susi 2008 Dynasty Trust, an entity through which Roger E. Susi has indirect beneficial ownership.
• Roger E. Susi also holds indirect beneficial ownership through the Roger E. Susi Revocable Trust and the Matthew Susi 2008 Dynasty Trust.

Stakeholder Impact

• Shareholders: May observe a slight decrease in insider ownership, though the pre-planned nature of the sale under a 10b5-1 plan typically mitigates concerns about management's confidence in the company's future.

Key Dates

Recommendation

The filing details a pre-scheduled sale of shares by a key executive under a Rule 10b5-1 trading plan. Such transactions are generally considered routine and do not typically signal a change in the company's fundamental outlook or warrant a strong buy or sell recommendation based solely on this information. Investors should consider this as a planned liquidity event rather than a reaction to new company-specific news, thus a 'hold' recommendation is appropriate as it does not provide new information to alter existing investment theses.

Keywords

IRADIMED, IRMD, Insider Trading, Stock Sale, Form 4, CEO, 10b5-1 Plan